1. Home
  2. CYTK vs BCPC Comparison

CYTK vs BCPC Comparison

Compare CYTK & BCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • BCPC
  • Stock Information
  • Founded
  • CYTK 1997
  • BCPC 1967
  • Country
  • CYTK United States
  • BCPC United States
  • Employees
  • CYTK N/A
  • BCPC N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • BCPC Major Chemicals
  • Sector
  • CYTK Health Care
  • BCPC Industrials
  • Exchange
  • CYTK Nasdaq
  • BCPC Nasdaq
  • Market Cap
  • CYTK 4.6B
  • BCPC 5.3B
  • IPO Year
  • CYTK 2004
  • BCPC N/A
  • Fundamental
  • Price
  • CYTK $49.76
  • BCPC $153.43
  • Analyst Decision
  • CYTK Buy
  • BCPC Strong Buy
  • Analyst Count
  • CYTK 15
  • BCPC 1
  • Target Price
  • CYTK $75.57
  • BCPC $189.00
  • AVG Volume (30 Days)
  • CYTK 2.7M
  • BCPC 134.4K
  • Earning Date
  • CYTK 11-05-2025
  • BCPC 10-24-2025
  • Dividend Yield
  • CYTK N/A
  • BCPC 0.56%
  • EPS Growth
  • CYTK N/A
  • BCPC 21.42
  • EPS
  • CYTK N/A
  • BCPC 4.36
  • Revenue
  • CYTK $85,738,000.00
  • BCPC $985,930,000.00
  • Revenue This Year
  • CYTK $330.96
  • BCPC $9.58
  • Revenue Next Year
  • CYTK $73.41
  • BCPC $6.32
  • P/E Ratio
  • CYTK N/A
  • BCPC $35.45
  • Revenue Growth
  • CYTK 2635.74
  • BCPC 5.74
  • 52 Week Low
  • CYTK $29.31
  • BCPC $145.70
  • 52 Week High
  • CYTK $59.39
  • BCPC $185.96
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 63.01
  • BCPC 37.26
  • Support Level
  • CYTK $49.22
  • BCPC $154.72
  • Resistance Level
  • CYTK $53.58
  • BCPC $159.25
  • Average True Range (ATR)
  • CYTK 2.54
  • BCPC 2.84
  • MACD
  • CYTK 0.29
  • BCPC -1.01
  • Stochastic Oscillator
  • CYTK 76.53
  • BCPC 5.66

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About BCPC Balchem Corporation

Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.

Share on Social Networks: